Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC66355 hRIO2 kinase ligand-1 Featured
hRIO2 kinase ligand-1 (com 9) is a ligand of hRIO2 kinase, with a Kd value of 520 nM.
More description
DC33606 CTX-0124143 Featured
CTX-012414 is a KAT6A inhibitor with IC50 value of 0.49 μM and KD value of 0.38 -M.
More description
DC66354 RIOK2-IN-1 Featured
RIOK2-IN-1 (com 4) is a potent and selective RIOK2 inhibitor (Kd=150 nM), but has low cellular activity (IC50=14,600 nM). RIOK2 is an atypical kinase associated with a variety of human cancers and is involved in ribosome maturation and cell cycle progression. The small molecule inhibitor CQ211 (HY-147655), an improvement of RIOK2-IN-1 as the lead compound, has good in vivo and in vitro activity, inhibits the proliferation of MKN-1 and HT-29 cancer cells, and can xenograft MKN in mice -1 model inhibits tumor progression.
More description
DC66353 Methyl 3,4,5-trimethoxycinnamate Featured
Methyl 3,4,5-trimethoxycinnamate (Compound III) is a natural compound with hydroxyl radical-scavenging effects.
More description
DC66352 Methyl 3,4-dimethoxycinnamate Featured
Methyl 3,4-dimethoxycinnamate is an inhibitor of uredospore germination. Methyl 3,4-dimethoxycinnamate also inhibits global DNA methylation in in Hep3B cells.
More description
DC66351 NorA-IN-1 Featured
NorA-IN-1 (Compound 16) is a NorA inhibitor. NorA-IN-1 inhibits NorA efflux pump in everted membrane vesicles. NorA-IN-1 can be used for research of multidrug resistance.
More description
DC66350 LM-41 Featured
LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells.
More description
DC37370 Sulphenone Featured
Sulphenone is a chemical that can be used for the control of mite. .
More description
DC66349 EBV lytic cycle inducer-1 Featured
Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers.
More description
DC66348 Scarlet 808 Featured
Scarlet 808 (Bronze Red; Shanghai Bronze Red) is a naphthol red pigment. Scarlet 808 can be used for coloring coatings, leather, and latex paints. It has the advantages of high tinting power, good hiding power, alkali resistance, and acid resistance.
More description
DCC2356 Gsk1733953a Featured
Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG
More description
DC70393 ETC-168 Featured
ETC-168 (ETC168) is a potent, selective MNK kinase inhibitor with biochemical IC50 of 23 and 43 nM against MNK1 and MNK2, respectively.ETC-168 acts as a MNK2-biased, dual-MNK inhibitor in cells.ETC-168 induced dose-dependent growth suppression and inhibited 50% of cell viability at 5 uM in LPS141 and MESSA, ETC-168 treatment elicited a consistent increase of cells in G0/G1 phase among LPS141, LP6, and MESSA cells in a dose-dependent manner. ETC-168 decreased cells of S and G2/M phases, while no significant induction of sub-G1 cells.Inhibition of MNK1/2 by ETC-168 elevated the expression of MNK1/2 at both transcript and protein levels in soft tissue sarcoma (STS) cells.ETC-168 effectively suppressed both p-4E and cell viability in MESSA cells, but not CGP57380 and eFT508.ETC-168 suppresseed phosphorylation of ribosomal protein S6 (RPS6) in sensitive STS cell, decreased expression of E2F1, FOXM1, and WEE1.Inhibition of MCL1 via S63845 synergizes with ETC-168 against STS cells.
More description
DC66347 HDL-16 Featured
HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function.
More description
DC66346 11β-HSD2-IN-2 Featured
11β-HSD2-IN-2 (compound 3) is a selective inhibitor for 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) with an IC50 of 300 nM.
More description
DC66345 CAY10464 Featured
CAY10464 (AHR antagonist 7; compound 4j) is a selective and high-affinity aryl hydrocarbon receptor (AhR) antagonist with a Ki of 1.4 nM.
More description
DC66344 (E/Z)-MCB-613 Featured
(E/Z)-MCB-613 is a pan-Steroid Receptor Coactivator (SRC) stimulator. (E/Z)-MCB-613 overstimulates SRC activity in cancer cells resulting in excessive generation of reactive oxygen species (ROS), leading to cell stress and death by a process called paraptosis. (E/Z)-MCB-613 is a cytotoxic molecule that plays an important role in cancer.
More description
DC66343 Antiviral agent 52 Featured
Antiviral agent 52 (Compound 30) is a Chlorcyclizine (HY-112067) derivative that exhibits antiviral activity against hepatitic C virus (HCV) with an EC50 of 17 nM. Antiviral agent 52 reveals cytotoxicity in cell Huh7.5.1 with CC50 of 21.3 μM.
More description
DC20234 PAQ Featured
PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells.
More description
DC66342 N-Benzyl-6-chloropyrimidin-4-amine Featured
N-Benzyl-6-chloropyrimidin-4-amine is a pyrimidine derivative.
More description
DC66341 P2X4 antagonist-1 Featured
P2X4 antagonist-1 (Compound 24) is an antagonist for P2X4 with IC50 of 15 nM.
More description
DC66340 CZL80 Featured
CZL80, a brain-penetrable caspase-1 inhibitor with an IC50 of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility.
More description
DC66339 N-Desmethyl-U-47700 Featured
N-Desmethyl-U-47700 is the primary metabolite of U-47700 (an opioid agonist).
More description
DCC4286 Psb-1491 Featured
Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)
More description
DC73510 Org 274179-0 Featured
Org 274179-0 is a highly potent, allosteric antagonist of the thyroid-stimulating hormone receptor (TSH receptor), inhibits bTSH-, hTSH- and M22-mediated CRE-luciferase transactivation in the CHO cell line.
More description
DC73933 C902 Featured
C902 is a small-molecule inhibitor targeting LIN28-let-7 interaction, shows dose-dependent inhibition in an EMSA validation assay with IC50 of 5 uM.
More description
DC66338 GW549390X Featured
GW549390X is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.26 μM and 1.2 μM, respectively. GW549390X can bind to the ATP pocket of FLuc through the aniline side chain and is an ATP-competitive inhibitor of Fluc. GW549390X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases, with potential implications for Fluc reporter assays.
More description
DCC4285 Psb-1434 Featured
Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)
More description
DC11911 Rovazolac Featured
Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
More description
DC66336 BD1063 HCl Featured
BD1063 is a selective sigma receptor antagonist, with a reported binding affinity of Ki = 9 ± 1 nM for the sigma-1 receptor and more than 49 times selectivity over the sigma-2 receptor. Consistent with other reported sigma receptor antagonists, pretreating Swiss Webster mice with BD1063 significantly decreases the convulsivity and lethality of cocaine. In other animal studies, BD1063 blocks the effects of MDMA, and reduces alcohol intake in rodent models of alcoholism.
More description
DC66335 ANO61 Featured
ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca2+ response with an IC50 of 47.7 μM.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X